Skip to main content
MedPathMedPath Home
Clinical Trials/NCT06155370
NCT06155370
Not yet recruiting
Not Applicable

Construction of Gynecological Tumor Organoids

Peking Union Medical College Hospital0 sites200 target enrollmentDecember 1, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsGynecologic CancerOrganoid

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gynecologic Cancer
Sponsor
Peking Union Medical College Hospital
Enrollment
200
Primary Endpoint
Construction of BioBank
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This study focuses on the construction of a biological sample library for organoids and tumor tissues in gynecological tumors.

Detailed Description

Explore the construction and maintenance of a large-scale queue of gynecological tumor organoids. Beijing Daxiang Technology Co., Ltd. provides corresponding technical support and chip design. Gynecological oncology center provides tumor samples, clinical information, and pathological support, and biological sample library provides technical support, storage space, and quality management.

Registry
clinicaltrials.gov
Start Date
December 1, 2023
End Date
December 1, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lei Li

professor

Peking Union Medical College Hospital

Eligibility Criteria

Inclusion Criteria

  • •Age of 18 or older, an informed consent form is provided;
  • •The preoperative tumor burden assessment and intraoperative researcher team believe that sampling is feasible;
  • •Having relevant requirements for sample library storage;
  • •Surgical treatment at Peking Union Medical College Hospital.

Exclusion Criteria

  • •Unable to meet all inclusion criteria;
  • •The research team considers any situations or considerations that may hinder normal pathological assessment.

Outcomes

Primary Outcomes

Construction of BioBank

Time Frame: one year

BioBank including organoids banks, tissue banks, PDX banks, immune cell banks, and primary banks from other tissue sources

Secondary Outcomes

  • Exploring the molecular mechanism based on organoids banks(one year)
  • Drug sensitivity detection based on organoids banks(one year)

Similar Trials

Unknown
Not Applicable
Tissue Bank of Biological Specimens From Patients With Gynecologic DiseaseEndometrial NeoplasmsUterine Cervical NeoplasmsOvarian NeoplasmsLeiomyoma
NCT00299481U.S. Army Medical Research and Development Command7,000
Not yet recruiting
Not Applicable
Construction of Gynecological Tumor Sample LibraryGynecologic Cancer
NCT06204354Peking Union Medical College Hospital2,500
Completed
Not Applicable
Pre-Clinical Models in Gynecological Tumors A Tissue RepositoryEndometrial NeoplasmsUterine Neoplasms
NCT00250783University of New Mexico26
Recruiting
Not Applicable
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot StudyEndometrial Cancer
NCT06603506Centre Francois Baclesse16
Completed
Not Applicable
Collecting Tumor Samples From Patients With Gynecological TumorsBorderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedChildhood Embryonal RhabdomyosarcomaChildhood Malignant Ovarian Germ Cell TumorEndometrioid Stromal SarcomaGestational Trophoblastic TumorMalignant MesotheliomaMalignant Ovarian Epithelial TumorMelanomaNeoplasm of Uncertain Malignant PotentialOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Serous CystadenocarcinomaPaget Disease of the VulvaRecurrent Cervical CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage I Ovarian CancerStage I Uterine Corpus CancerStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IA Ovarian Germ Cell TumorStage IB Cervical CancerStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IB Ovarian Germ Cell TumorStage IC Fallopian Tube CancerStage IC Ovarian CancerStage IC Ovarian Germ Cell TumorStage II Ovarian CancerStage II Uterine Corpus CancerStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIA Ovarian Germ Cell TumorStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian CancerStage IIB Ovarian Germ Cell TumorStage IIC Fallopian Tube CancerStage IIC Ovarian CancerStage IIC Ovarian Germ Cell TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage III Cervical CancerStage III Uterine Corpus CancerStage III Vaginal CancerStage III Vulvar CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal CancerStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerStage IV Uterine Corpus CancerStage IVA Cervical CancerStage IVA Vaginal CancerStage IVB Cervical CancerStage IVB Vaginal CancerStage IVB Vulvar CancerUterine Corpus CancerUterine Corpus LeiomyosarcomaVulvar Squamous Cell Carcinoma
NCT00897442Gynecologic Oncology Group275